MYC and metabolic dysfunction-associated steatotic liver disease: These findings identify the GPR3 to β-arrestin2 to PKM2 and to c-Myc pathway as a critical component of metabolic reprogramming in macrophages and activation of this pathway in KCs as a promising approach for treating obesity and NAFLD.